Loading...
•
Mar 31, 2024
McKesson Q4 2024 Earnings Report
McKesson's Q4 2024 earnings decreased by 14% due to a higher tax rate, partially offset by a lower share count, and growth in the U.S. Pharmaceutical segment.
Key Takeaways
McKesson Corporation reported an 11% increase in fourth-quarter revenues, reaching $76.4 billion. However, adjusted earnings per diluted share decreased by 14% to $6.18, driven by a higher tax rate, partially offset by a lower share count and growth in the U.S. Pharmaceutical segment.
Consolidated revenues increased by 11% to $76.4 billion.
Earnings per diluted share from continuing operations increased by $0.31 to $6.02.
Adjusted Earnings per Diluted Share decreased by 14% to $6.18.
Growth in revenue was primarily driven by the U.S. Pharmaceutical segment.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson anticipates Fiscal 2025 Adjusted Earnings per Diluted Share of $31.25 to $32.05 reflecting continued operating momentum, a strong financial position, and a balanced approach to capital deployment.
Positive Outlook
- Continued operating momentum
- Strong financial position
- Balanced approach to capital deployment
- Focus on company priorities
- Leveraging assets and capabilities to drive sustainable growth
Revenue & Expenses
Visualization of income flow from segment revenue to net income